Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLUE 
Monte Rosa Therapeutics Inc (GLUE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: GLUE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.2
1 Year Target Price $17.2
| 6 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.78% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.05B USD | Price to earnings Ratio 50.53 | 1Y Target Price 17.2 |
Price to earnings Ratio 50.53 | 1Y Target Price 17.2 | ||
Volume (30-day avg) 9 | Beta 1.62 | 52 Weeks Range 3.50 - 16.66 | Updated Date 12/1/2025 |
52 Weeks Range 3.50 - 16.66 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.32 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.36 | Actual -0.33 |
Profitability
Profit Margin 11.54% | Operating Margin (TTM) -258.26% |
Management Effectiveness
Return on Assets (TTM) 1.37% | Return on Equity (TTM) 9.28% |
Valuation
Trailing PE 50.53 | Forward PE 10.02 | Enterprise Value 701864195 | Price to Sales(TTM) 5.8 |
Enterprise Value 701864195 | Price to Sales(TTM) 5.8 | ||
Enterprise Value to Revenue 3.87 | Enterprise Value to EBITDA 41.68 | Shares Outstanding 65117761 | Shares Floating 28946147 |
Shares Outstanding 65117761 | Shares Floating 28946147 | ||
Percent Insiders 0.69 | Percent Institutions 105.56 |
Upturn AI SWOT
Monte Rosa Therapeutics Inc
Company Overview
History and Background
Monte Rosa Therapeutics was founded in 2018 to develop novel small molecule protein degraders. The company is focused on leveraging its QuEEN (Quinary E3 ligase Enhancer Network) platform to design and develop novel molecular glue degrader therapeutics.
Core Business Areas
- Protein Degradation Therapeutics: Development of small molecule protein degraders targeting disease-causing proteins using its QuEEN platform.
Leadership and Structure
Markus Warmuth, M.D., is the CEO. The company has a management team covering research, development, and business operations, supported by a Board of Directors with expertise in drug discovery and development.
Top Products and Market Share
Key Offerings
- MRT-2359: MRT-2359 is an oral GSPT1 degrader in Phase 1/2 clinical trials for MYC-driven cancers. Competitors include companies developing other targeted therapies and protein degradation technologies, such as Arvinas and C4 Therapeutics.
- MRT-0085: MRT-0085 is a molecular glue degrader in preclinical development targeting a undisclosed target. Competitors include companies developing protein degradation therapies.
Market Dynamics
Industry Overview
The protein degradation field is rapidly evolving, attracting significant investment and interest. The industry is characterized by intense competition and technological innovation in the discovery and development of novel degradation approaches.
Positioning
Monte Rosa is positioned as a leader in the molecular glue-based protein degradation field, with a proprietary QuEEN platform and a focus on developing highly selective and potent degraders.
Total Addressable Market (TAM)
The TAM for protein degradation therapies is significant, potentially reaching billions of dollars across various disease areas, particularly in oncology and immunology. Monte Rosa is positioned to capture a portion of this TAM through its innovative technology and pipeline of degrader candidates.
Upturn SWOT Analysis
Strengths
- Proprietary QuEEN platform technology
- Experienced leadership team
- Promising preclinical and clinical data
- Strong intellectual property position
Weaknesses
- Early-stage clinical development
- Reliance on single technology platform
- High cash burn rate
- Limited number of clinical programs
Opportunities
- Expansion of the pipeline with new degrader candidates
- Partnerships and collaborations with larger pharmaceutical companies
- Clinical validation of the QuEEN platform
- Expansion into new therapeutic areas
Threats
- Competition from other protein degradation companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- ARVN
- C4TX
- KYMR
Competitive Landscape
Monte Rosa has a proprietary technology with great potential. They are competing against companies in the broader targeted therapy area. They have a unique and competitive approach within this arena.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth has been characterized by the advancement of its pipeline through preclinical and early clinical development.
Future Projections: Future growth is dependent on the successful development and commercialization of its degrader candidates. Analyst estimates vary, but generally project significant revenue potential upon successful product launches.
Recent Initiatives: Recent initiatives include advancing MRT-2359 in clinical trials, expanding the pipeline with new degrader candidates, and presenting data at scientific conferences.
Summary
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel molecular glue degrader therapeutics. Its QuEEN platform is a unique approach. The company's success depends on advancing its clinical programs, mitigating risks, and securing partnerships to support future growth. Clinical data will be a key event that the company needs to look out for.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is based on estimated revenue, market participants and size. Actual values may differ.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monte Rosa Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-06-24 | President, CEO & Director Dr. Markus Warmuth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 147 | Website https://www.monterosatx.com |
Full time employees 147 | Website https://www.monterosatx.com | ||
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.